Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001996 · ClinicalTrials.gov registry record · Phase 2
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
A Phase 2 study of HIV Infections and Pneumonia, Pneumocystis Carinii, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00001996 is a Phase 2 study of HIV Infections and Pneumonia, Pneumocystis Carinii that has completed, run by Glaxo Wellcome. The trial reports 20 study locations across 9 states.
The verdict
NCT00001996, a Phase 2 study of HIV Infections and Pneumonia, Pneumocystis Carinii, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the incidence of premature discontinuation of therapy due to toxicity. To compare the efficacy of 566C80 with intravenous (IV) pentamidine for the treatment of mild to moderate PCP in the same population.
Conditions Studied
Interventions
- DRUG Atovaquone
- DRUG Pentamidine isethionate
Study Locations (20)
California
- East Bay AIDS Ctr - Berkeley
- Kaiser Foundation Hosp - Harbor City
- Cedars Sinai Med Ctr - Los Angeles
- UCLA CARE Ctr - Los Angeles
- UCI Med Ctr - Orange
- AIDS Community Research Consortium - Redwood City
- Davies Med Ctr - San Francisco
- Dr Patrick Joseph - San Ramone
New York
- Beth Israel Med Ctr - New York
- Saint Vincent's Hosp and Med Ctr - New York
- Harlem AIDS Treatment Group / Harlem Hosp Ctr - New York
Massachusetts
- Massachusetts Gen Hosp - Boston
- Boston City Hosp - Boston
Texas
- Gathe, Joseph, M.D. - Houston
- Baylor College of Medicine - Houston
Georgia
- Infectious Disease Research Consortium of Georgia - Atlanta
Ohio
- Univ of Cincinnati - Cincinnati
Oregon
- Portland Veterans Adm Med Ctr / Rsch & Education Grp - Portland
Pennsylvania
- Buckley Braffman Stern Med Associates - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001996
The ClinicalTrials.gov registry entry for NCT00001996 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Atovaquone is the first listed.
NCT00001996 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00001996 about?
NCT00001996 is a clinical study titled "A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole". To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the incidence of premature discontinu...
What is the current status of trial NCT00001996?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00001996 study?
This clinical trial studies the following conditions: HIV Infections, Pneumonia, Pneumocystis Carinii.
What interventions are being tested in trial NCT00001996?
The interventions under investigation include: Atovaquone (DRUG), Pentamidine isethionate (DRUG).
Who is sponsoring clinical trial NCT00001996?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001996 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.